Enrolling by invitationNCT06262282
Mycobacteriophage Treatment of Non-tuberculosis Mycobacteria
Studying Cystic fibrosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Jewish Health
- Principal Investigator
- Jerry Nick, MDNational Jewish Health
- Intervention
- mycobacteriophage(biological)
- Enrollment
- 10 enrolled
- Eligibility
- 6 years · All sexes
- Timeline
- 2024 – 2028
Study locations (18)
- University of Alabama, Birmingham, Alabama, United States
- Children's Hospital of Los Angeles, Los Angeles, California, United States
- University of California, San Diego, California, United States
- Childrens Hospital Colorado, Denver, Colorado, United States
- National Jewish Health, Denver, Colorado, United States
- University of Florida, Gainesville, Florida, United States
- Northwestern University, Chicago, Illinois, United States
- John Hopkins University, Baltimore, Maryland, United States
- Boston Childrens Hospital, Boston, Massachusetts, United States
- University of Michigan, Ann Arbor, Michigan, United States
- Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States
- Columbia University, New York, New York, United States
- University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
- Nationwide Children's Hospital, Columbus, Ohio, United States
- University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
- +3 more locations on ClinicalTrials.gov
Collaborators
Cystic Fibrosis Foundation
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06262282 on ClinicalTrials.govOther trials for Cystic fibrosis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07437105Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-272 in Healthy ParticipantsVertex Pharmaceuticals Incorporated
- RECRUITINGNANCT07436351ACT With CF Self-Help ToolkitThomas Jefferson University
- RECRUITINGNCT07083557Routine Validation and Reproducibility Testing of Laboratory Assays and Research Techniques Used for Endocrine, Cardiometabolic, and Musculoskeletal Disorder Research (VALD)Bettina Mittendorfer
- RECRUITINGNANCT07314229Prevalence of Exercise-induced Ventilatory Limitation and Associated Factors in Patients With Cystic Fibrosis Receiving Elexacaftor-Tezacaftor-IvacaftorUniversity Hospital, Lille
- RECRUITINGNCT07369414Environmental Reservoirs of Non-tuberculous Mycobacteria in Cystic Fibrosis Households: A Case-control Study of Exposure Risk at HomeResearch Center Borstel
- RECRUITINGNCT07505797ATUSA Ultrasound Diagnostic Imaging for Breast Lesions Evaluation (AUDIBLE)iSono Health, Inc.
- RECRUITINGPHASE1NCT07283770Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-581 in Healthy ParticipantsVertex Pharmaceuticals Incorporated
- RECRUITINGNCT07363304Impact of Elexacaftor-Tezacaftor-Ivacaftor Treatment on Metabolic, Epigenetic and Fecal Microbiota Profiles in People With Cystic Fibrosis.Meyer Children's Hospital IRCCS